09.06.26 -- Stopping A Drug Development Program Sometimes Creates More Value Than Continuing

Good R&D leadership is knowing when to keep investing in a development program, when to change course, and when to return to base, writes David Adler, M.D./Ph.D., MBA.

Precision oncology only works when biomarker testing helps identify the right patients at scale before launch, explains Boehringer Ingelheim’s Vicky Brown.

On this week's episode of the Business of Biotech, Olivier Litzka, Partner at Andera Partners, talks about what it really takes for biotech companies to attract capital, stay focused, and survive the moments when biology and execution punch back.

Struggling with siloed or inconsistent trial data? This guide outlines a clear path to cleaner, governed, AI-ready datasets.

Psychedelic trials require unique operational approaches. Discover how to address patient safety, blinding, specialized assessments, and therapeutic setting considerations.

Ophthalmic trials lose participants at twice the rate of other studies. Point-of-need assessment delivery cuts dropout from 30% to 9% and reduces travel burden by 80.6%, protecting your endpoint data.

A layoff became the spark for building a nimble analytical lab serving pharma and beyond. See how expertise, adaptability, and calculated risk-taking can unlock faster problem-solving.

Examine five critical supply chain gaps in cell and gene therapy logistics that put patients at risk, from invisible operational burdens to reactive monitoring and fragmented coordination strategies.

Learn how to implement PAT effectively with a roadmap that covers techniques, validation, data integrity, and lifecycle strategies to help teams improve quality, control, and productivity.

To truly maximize enrollment in decentralized models, sponsors must invest in human connection to build the trust needed to move patients from awareness to active participation.